TLDR:
- Biolinq, a San Diego-based healthcare technology company, raised $58M in funding led by Alpha Wave Ventures.
- The company plans to use the funds to support the completion of a U.S. pivotal clinical trial this year evaluating its proprietary intradermal glucose sensor.
Biolinq, a healthcare technology company based in San Diego, CA, recently announced that they have secured $58M in funding. The funding round was led by Alpha Wave Ventures, with participation from Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures, as well as existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, Aphelion Capital, Senvest Management, Features Capital, and Taisho Pharmaceutical.
The main goal for the company with this funding is to support the completion of a pivotal clinical trial in the U.S. this year. The trial will be evaluating Biolinq’s proprietary intradermal glucose sensor, with the subsequent plan to submit the findings to the FDA for approval. CEO Rich Yang expressed excitement about the potential impact of their technology, stating that it enables access to a metabolically active compartment of the skin for biosensing without the need for needles or causing bleeding.
Biolinq focuses on providing precision multi-analyte wearable sensors to improve metabolic health. Their technology aims to give a comprehensive view of metabolic health by combining glucose information with contextual data about daily activities all in one device.
